Beijing, Sep 14 (Prensa Latina) The Shanghai Fosun Pharmaceutical company from China foresees to commercialize since next winter the anti Covid-19 vaccine, developed together with the German BioNTech, if it demonstrates effectiveness in the last clinical trials, the local press reported today.
According to the information, if the desired results are achieved, the company would offer 10 million doses of the medicine to Hong Kong, with the purpose of immunizing five million people.
In addition, the company plans to produce more than 100 million doses this year and 1.3 billion in 2021 for global distribution.
At the same time, Fosun Pharma seeks the approval of the National Medical Products Administration in order to articulate the data of the tests made in China and abroad, where more than 25 thousand volunteers participate.
The BNT162b2 -developed with mRNA technology- is one of the 10 vaccination candidates that China is researching in humans to fight the coronavirus SARS-CoV-2 and its deadly pneumonia.
Four of these preparations are in the final stage of trials and two of them are of the inactivated type and could be released on the market next December for less than one thousand yuan (144.00 dollars) for two doses.
The recombinant Ad5-nCoV is the only one so far with a patent and would also be marketed soon at about 100 yuan (US$14.64) for each dose.
In July, China approved the urgent use of some vaccines and administered them to more than 100,000 foreign service personnel, military personnel in UN peacekeeping missions, and health and aviation employees.
However, its authorities are coordinating with the World Health Organization on the requirements needed to approve the sale of any such products.
The Asian country registers at least 4,741 deaths and 90,709 confirmed cases of Covid-19, to date.
Hong Kong continues to have the worst case scenario due to the outbreak in July and a border city in Yunnan province is under quarantine after detecting two patients imported from Myanmar.